SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TREND1, conix, MadHatter326, KingDMC, $Pistol Pete$
Search This Board:
Last Post: 8/28/2015 3:10:31 PM - Followers: 313 - Board type: Free - Posts Today: 13


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 08/18/2015 04:31:53 PM
MNKD News: Current Report Filing (8-k) 08/13/2015 08:54:27 AM
MNKD News: Quarterly Report (10-q) 08/10/2015 06:23:32 PM
MNKD News: Current Report Filing (8-k) 08/10/2015 08:03:02 AM
MNKD News: Current Report Filing (8-k) 07/29/2015 08:57:16 AM
#14243  Sticky Note SHORT INTEREST--As of 8/14/2015 ---121,777,505 shares conix 08/27/15 11:06:42 AM
#13561  Sticky Note $MNKD MannKind Relies on 'Death Spiral' Fi $Pistol Pete$ 07/29/15 06:48:01 PM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#14273   What's Behind Sanofi's Afrezza Pediatric Study For MannKind?What's robert sacher 08/28/15 03:10:31 PM
#14272   Will Afrezza Replace Orals In Insulin Therapy? robert sacher 08/28/15 03:07:50 PM
#14271   Is this better than "CHANCE OF" lung cancer ? TREND1 08/28/15 01:54:44 PM
#14270   How will affect AFREZZA sales TREND1 08/28/15 01:36:00 PM
#14269   Looking at your chart ... JLS 08/28/15 01:19:29 PM
#14268   T1, JLS 08/28/15 01:05:17 PM
#14267   Test2 JLS 08/28/15 12:56:36 PM
#14266   Learn WYCKOFF so you can do options better TREND1 08/28/15 12:47:07 PM
#14265   MNKD D showing WYCKOFF AREA( RED) using AR TREND1 08/28/15 12:44:49 PM
#14264   JLS You think you know TEST 2 TREND1 08/28/15 12:39:10 PM
#14263   TREND1, JLS 08/28/15 12:22:31 PM
#14262   It is working again. miles away 08/28/15 10:38:57 AM
#14261   BATS BOOK VIEWER IS NOT WORKING, DO YOU miles away 08/28/15 09:38:03 AM
#14260   JLS You made HAL mad. TREND1 08/27/15 10:35:38 PM
#14259   Uhhhh ... JLS 08/27/15 09:39:22 PM
#14258   TREND1, JLS 08/27/15 09:26:50 PM
#14257   Amazing Cramer quit being totally negative and said kugel 08/27/15 07:29:36 PM
#14256   September is going to be a game changer Hypi 08/27/15 06:32:48 PM
#14255   $MNKD nice closed again on the second day up $Pistol Pete$ 08/27/15 06:02:25 PM
#14254   JLS You are right. TREND1 08/27/15 06:02:12 PM
#14253   TREND1, JLS 08/27/15 05:11:30 PM
#14252   Cool !! mc67 08/27/15 01:54:53 PM
#14251   Interesting read. The Endo's are talking. Denise Chanterelle 08/27/15 01:41:48 PM
#14250   Afrezza is covered by Medicare, Medicaid, DOD, Medigap, Denise Chanterelle 08/27/15 01:31:26 PM
#14249   Researchers successfully transplant insulin-producing cells via new technique TREND1 08/27/15 01:30:28 PM
#14248   Thanks for the info, TREND1. I do not conix 08/27/15 12:29:32 PM
#14247   Thanks. MNKD Sup/Res: JLS 08/27/15 12:13:33 PM
#14246   test 2 update sold MNKD at 3.94 TREND1 08/27/15 12:10:40 PM
#14245   CONIX Do you have an extra account at stock TREND1 08/27/15 11:52:38 AM
#14244   RSI is still low with room to run, conix 08/27/15 11:49:15 AM
#14243   SHORT INTEREST--As of 8/14/2015 ---121,777,505 shares conix 08/27/15 11:06:42 AM
#14242   Test 2 sell limit is set at 3.94 TREND1 08/27/15 09:43:14 AM
#14241   Thanks for your time and perspective. Much appreciated. Southbird66 08/26/15 11:42:45 PM
#14240   To tell you the truth ... JLS 08/26/15 11:37:50 PM
#14239   O.K. Ratio is only down a bit, Southbird66 08/26/15 10:31:04 PM
#14238   MNKD Short Sale Volume Ratio JLS 08/26/15 08:22:56 PM
#14237   Nice big spike in buy volume at the Southbird66 08/26/15 06:16:44 PM
#14236   $MNKD nice trade today $Pistol Pete$ 08/26/15 04:03:03 PM
#14235   Congrats $Pistol Pete$ 08/26/15 04:02:39 PM
#14234   Will this hurt MNKD ? TREND1 08/26/15 02:17:13 PM
#14233   I may have lucked into a great buy conix 08/26/15 01:46:41 PM
#14232   More room for MNKD for type 1 TREND1 08/26/15 12:04:22 PM
#14231   test 2 sell for MNKD reduced to 3.98 TREND1 08/26/15 11:55:05 AM
#14230   Agree. I have set my buying order COO2002COO 08/25/15 10:18:03 PM
#14229   Your prediction is correct. MNKD closed today at $Pistol Pete$ 08/25/15 07:32:53 PM
#14228   Insurance coverage = ounce of prevention... ? mc67 08/25/15 06:46:50 PM
#14227   Market will test the lows again unfortunately. This KingDMC 08/25/15 04:55:51 PM
#14226   * * $MNKD Video Chart 08-25-15 * * ClayTrader 08/25/15 04:55:20 PM
#14225   So ... JLS 08/25/15 04:05:22 PM
#14224   Good strong finish.. kugel 08/25/15 04:03:56 PM